Last reviewed · How we verify
PLX-200
PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.
PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | PLX-200 |
|---|---|
| Also known as | Gemfibrozil |
| Sponsor | Polaryx Therapeutics, Inc. |
| Drug class | PLK1 inhibitor |
| Target | PLK1 (Polo-like kinase 1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PLK1 is a serine/threonine kinase essential for mitotic progression and cytokinesis. By inhibiting PLK1, PLX-200 prevents proper cell cycle checkpoint control, leading to mitotic catastrophe and apoptosis in rapidly dividing cancer cells. This mechanism is particularly effective in tumors with dysregulated cell cycle control.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLX-200 CI brief — competitive landscape report
- PLX-200 updates RSS · CI watch RSS
- Polaryx Therapeutics, Inc. portfolio CI